Universal Ibogaine (FRA:JC4) EBITDA Margin %: 7.62% (As of Apr. 2025)


What is Universal Ibogaine EBITDA Margin %?

Universal Ibogaine FRA:JC4 EBITDA Margin % is 7.62% as of Apr. 2025.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Universal Ibogaine's EBITDA for the three months ended in Apr. 2025 was €0.03 Mil. Universal Ibogaine's Revenue for the three months ended in Apr. 2025 was €0.45 Mil. Therefore, Universal Ibogaine's EBITDA margin for the quarter that ended in Apr. 2025 was 7.62%.

Universal Ibogaine  (FRA:JC4) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Universal Ibogaine EBITDA Margin % Related Terms

Universal Ibogaine EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine EBITDA Margin % Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 -948.65 -191.77 -66.05

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.98 -110.64 -52.45 -48.00 7.62

FRA:JC4 vs LABT, CALC, LNAI: EBITDA Margin % Comparison

For the Biotechnology subindustry, Universal Ibogaine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's EBITDA Margin % falls into.


Universal Ibogaine EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Universal Ibogaine's EBITDA Margin % for the fiscal year that ended in Jul. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2024 )/Revenue (A: Jul. 2024 )
=-1.035/1.567
=-66.05 %

Universal Ibogaine's EBITDA Margin % for the quarter that ended in Apr. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Apr. 2025 )/Revenue (Q: Apr. 2025 )
=0.034/0.446
=7.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 7.62% mean?
Universal Ibogaine (FRA:JC4) has a EBITDA Margin % of 7.62% as of Apr. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's EBITDA Margin % too high?
Universal Ibogaine's current EBITDA Margin % is 7.62%.
How does Universal Ibogaine's EBITDA Margin % compare to LABT and CALC?
Universal Ibogaine's EBITDA Margin % of 7.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current EBITDA Margin % is 7.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (FRA:JC4) has a current EBITDA Margin % of 7.62%. The current EBITDA Margin % is 7.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Universal Ibogaine (FRA:JC4), the current EBITDA Margin % is 7.62% as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.